Mycodot by ICT at Test Zone Diagnostic Center

Mycodot by ICT at Test Zone Diagnostic Center

The Mycodot by ICT (Immunochromatographic Test) is a rapid serological assay designed for the qualitative detection of specific antibodies (IgG, IgM, and IgA) directed against Mycobacterium tuberculosis antigens in human serum, plasma, or whole blood. This diagnostic tool is utilized as an aid in the clinical evaluation of patients suspected of having active tuberculosis (TB) infection. Developed to provide rapid diagnostic insights, the test utilizes lateral flow immunochromatographic technology, which allows for the visual detection of antigen-antibody complexes within a matter of minutes. At Test Zone Diagnostic Center in Peshawar, Pakistan, this test is conducted under strict laboratory standards to assist clinicians in the early screening and management of tuberculosis, a major public health concern in the region.

The underlying technology of the Mycodot by ICT relies on a nitrocellulose membrane pre-coated with highly specific recombinant antigens of Mycobacterium tuberculosis, such as the 38kDa antigen, 16kDa antigen, and lipoarabinamannan (LAM). When a patient's blood sample is introduced to the test device, any circulating antibodies specific to these TB antigens bind to colloidal gold-conjugated antigens present in the conjugate pad. As this mixture migrates along the membrane via capillary action, it encounters the immobilized capture antigens on the test line. If antibodies are present, a visible colored band forms, indicating a positive result. A separate control line must always appear to validate the procedural integrity of the test, confirming that adequate sample volume and lateral flow have occurred.

From an anatomical and physiological perspective, the Mycodot by ICT does not image a specific body region; rather, it evaluates the systemic humoral immune response of the host to an active or past infection by Mycobacterium tuberculosis. This pathogenic bacterium primarily targets the pulmonary parenchyma (lungs), leading to pulmonary tuberculosis. However, it can also disseminate hematogenously or lymphatically to other organs, causing extra-pulmonary tuberculosis in structures such as the pleura, lymph nodes, central nervous system, bones, joints, and genitourinary tract. The diagnostic value of the Mycodot test lies in its ability to quickly detect the host's immunological reaction to these bacterial antigens, providing a rapid, non-invasive screening option when sputum collection is difficult or when immediate clinical decisions are required.

While the Mycodot by ICT offers significant benefits in terms of speed, simplicity, and minimal sample requirements, it is essential to interpret its results within a comprehensive clinical framework. Modern medical guidelines, including those from the World Health Organization (WHO), emphasize that serological tests for tuberculosis should not be used as the sole basis for diagnosing active TB. This is because antibody levels can persist long after a patient has been successfully treated, and the test may not reliably distinguish between active disease, latent tuberculosis infection (LTBI), or prior exposure. Therefore, at Test Zone Diagnostic Center, pathologists and clinicians recommend correlating Mycodot results with definitive diagnostic modalities, such as sputum Acid-Fast Bacilli (AFB) smear microscopy, mycobacterial culture, chest X-rays, and molecular assays like GeneXpert MTB/RIF.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of accuracy and safety during the Mycodot by ICT procedure, patients are advised to follow these preparation guidelines:

• No Fasting Required: Patients do not need to fast before the test. You may eat and drink normally prior to your appointment at Test Zone Diagnostic Center.
• Medication Disclosure: Inform your physician and the laboratory staff of all medications you are currently taking, particularly immunosuppressants, corticosteroids, or chemotherapy, as these can suppress the immune response and potentially lead to false-negative antibody results.
• Medical History: Provide a brief history of any past tuberculosis infections, BCG vaccinations, or recent exposure to individuals with active TB, as this history is vital for the clinical interpretation of serological findings.
• Hydration: Stay well-hydrated before the blood draw, as this makes the veins more accessible and facilitates a smoother venipuncture process.
• Comfortable Clothing: Wear a short-sleeved shirt or clothing with sleeves that can be easily rolled up above the elbow to allow clear access to the venipuncture site.

During the Procedure

The collection of the blood sample for the Mycodot by ICT is a standard, minimally invasive procedure performed by experienced phlebotomists at Test Zone Diagnostic Center:

• Patient Positioning: The patient is seated comfortably in a blood collection chair, and the arm is extended and supported on an armrest.
• Site Selection and Cleansing: The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa (creek of the elbow). The skin over the selected vein is thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) and allowed to air dry to prevent contamination.
• Tourniquet Application: A sterile elastic tourniquet is applied a few inches above the venipuncture site to increase venous pressure, making the vein more visible and palpable.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection tube (typically a gold-top serum separator tube or red-top clot activator tube) is gently inserted into the vein. The patient may feel a brief, mild pinch or prick.
• Sample Collection: Once the required volume of blood (usually 3 to 5 milliliters) is collected, the tourniquet is released, the needle is gently withdrawn, and a sterile cotton ball or gauze pad is pressed onto the puncture site to control bleeding.
• Post-Collection Care: An adhesive bandage is applied over the site. The patient is advised to keep the bandage on for a few hours and avoid heavy lifting with that arm for the rest of the day.
• Laboratory Processing: The collected blood sample is allowed to clot, and then centrifuged to separate the serum. The clear serum is then applied to the Mycodot ICT cassette along with a specific buffer solution. The reaction is monitored, and the result is read visually by a laboratory technologist within 15 to 20 minutes.

When is a Mycodot by ICT Performed?

Evaluation of Suspected Pulmonary Tuberculosis

Physicians frequently request the Mycodot by ICT when a patient presents with classic symptoms of pulmonary tuberculosis, such as a persistent cough lasting more than three weeks, hemoptysis (coughing up blood), unexplained weight loss, drenching night sweats, and low-grade evening fevers. In regions with a high prevalence of TB, like Peshawar, this rapid test serves as an initial screening aid to quickly assess the likelihood of tuberculous infection while more definitive, time-consuming tests (like mycobacterial cultures) are being processed in the laboratory.

Screening in Resource-Limited or Urgent Settings

In clinical scenarios where rapid decision-making is critical or where advanced molecular diagnostics are temporarily unavailable, the Mycodot by ICT provides a valuable, rapid alternative. Because the test does not require specialized laboratory infrastructure, electricity, or highly complex equipment, it allows clinicians to obtain preliminary immunological data within minutes. This is particularly useful in outpatient clinics and community health screenings to identify patients who require immediate isolation, further diagnostic workup, or close clinical monitoring.

Investigation of Suspected Extra-Pulmonary Tuberculosis

Diagnosing extra-pulmonary tuberculosis (EPTB) presents a significant clinical challenge because obtaining tissue or fluid samples from deep-seated sites (such as the pleural cavity, lymph nodes, joints, or meninges) can be difficult, invasive, and sometimes inconclusive. Sputum smears are often negative in these patients. In such cases, the Mycodot by ICT can be performed to detect systemic anti-TB antibodies, offering supportive diagnostic evidence of mycobacterial exposure and assisting the physician in building a clinical case for EPTB when combined with imaging and clinical findings.

Adjunct Diagnostic Workup in Complex Cases

In complex clinical cases where initial sputum smears for Acid-Fast Bacilli (AFB) are negative, but the clinical suspicion of tuberculosis remains high, the Mycodot by ICT is used as an adjunctive diagnostic tool. A positive antibody test, when interpreted alongside abnormal chest radiographs (showing infiltrates, cavitary lesions, or hilar lymphadenopathy) and elevated inflammatory markers, can strengthen the clinical suspicion of TB, prompting the physician to initiate empirical treatment or pursue more invasive diagnostic procedures like bronchoscopy or tissue biopsy.

Epidemiological and Contact Tracing Assessments

The Mycodot by ICT can also be utilized during epidemiological investigations and contact tracing programs to assess immunological exposure among individuals who have been in close contact with confirmed active tuberculosis patients. While it cannot distinguish between active disease and latent infection, detecting anti-TB antibodies helps identify individuals who have mounted an immune response to the bacterium, guiding healthcare providers in determining who requires further clinical surveillance, chest imaging, or preventive therapy.

What Does a Mycodot by ICT Detect?

The Mycodot by ICT is designed to detect and evaluate several immunological and procedural parameters, which include:

• Anti-Mycobacterium tuberculosis IgG Antibodies: Detects long-term humoral immune response, which may indicate active, latent, or past resolved tuberculosis infection.
• Anti-Mycobacterium tuberculosis IgM Antibodies: Detects early-phase immunoglobulins, which are typically produced during the acute or early stages of active infection.
• Anti-Mycobacterium tuberculosis IgA Antibodies: Evaluates mucosal-associated immunoglobulins, which are often elevated in active pulmonary tuberculosis.
• Immune Response to Recombinant 38kDa Antigen: Detects antibodies against one of the most immunogenic cell-wall proteins of M. tuberculosis, highly specific for active disease.
• Immune Response to 16kDa Antigen: Identifies antibodies against heat-shock proteins of the bacterium, which are commonly elevated in active infections.
• Immune Response to Lipoarabinamannan (LAM): Evaluates antibodies against the major lipopolysaccharide component of the mycobacterial cell wall.
• Procedural Validity via Control Line (C-line): Verifies that the lateral flow assay functioned correctly and that sufficient sample was applied.
• Presence of Active Pulmonary Tuberculosis: Strongly suggested when positive results correlate with classic clinical symptoms and positive chest X-ray findings.
• Presence of Extra-Pulmonary Tuberculosis: Supported when positive results occur in patients with localized non-pulmonary symptoms (e.g., pleural effusion, lymphadenitis).
• Latent Tuberculosis Infection (LTBI): Detected via persistent antibody presence in asymptomatic individuals with prior exposure.
• Past Resolved Tuberculosis: Indicated by positive antibody detection in patients with a history of successfully treated TB, as antibodies can persist for years.
• Cross-Reactivity with Non-Tuberculous Mycobacteria (NTM): Detects potential immunological cross-reactions with atypical mycobacteria (e.g., M. avium-intracellulare).
• Anergy or Immunosuppression Effects: Identified indirectly when a patient with active, culture-proven TB tests negative due to an inability to produce antibodies (e.g., advanced HIV, severe malnutrition).
• Early-Stage Infection: May result in a negative finding if the blood sample is collected before the patient's immune system has produced detectable levels of antibodies (window period).
• Serum Sample Suitability: Evaluates whether the specimen is free from severe hemolysis, lipemia, or icterus, which could interfere with the visual reading of the test band.
• BCG Vaccination Influence: Evaluates the potential (though minimal with recombinant antigens) of prior BCG vaccination to cause low-level antibody reactivity.
• Antibody Titer Intensity: Visually assesses the strength of the test line, which can range from weakly positive to strongly positive, reflecting antibody concentration.
• Systemic Immune Activation: Reflects the activation of B-lymphocytes in response to mycobacterial antigens circulating in the lymphatic or vascular systems.
• Need for Confirmatory Molecular Testing: A positive or negative result highlights the clinical necessity to perform confirmatory testing like GeneXpert MTB/RIF.
• Need for Microbiological Correlation: Directs clinicians to perform sputum AFB smear and culture to confirm the presence of viable, replicating bacilli.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Peshawar, we understand that timely diagnostic results are critical for patient management and peace of mind. The Mycodot by ICT is a rapid test, and our laboratory is optimized to process blood samples efficiently. Under standard operating procedures, the turnaround time for the Mycodot by ICT report is typically within 2 to 4 hours from the time of sample collection. This rapid processing ensures that physicians can make prompt clinical decisions regarding isolation, treatment, or further diagnostic testing.

Patients and referring physicians can access test reports through multiple convenient channels. Once the report is verified by our consultant pathologist, an automated SMS notification is sent to the patient's registered mobile number. Reports can be viewed and downloaded online via the secure Test Zone Diagnostic Center patient portal. Physical copies of the reports can also be collected directly from our main reception desk or any of our official collection centers across the region. Our digital reporting system ensures that your medical records are stored securely and are easily accessible whenever needed.

Mycodot by ICT Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-TB IgG Antibodies	Negative (No band visible at the IgG test region)	Positive (Visible band indicating presence of long-term antibodies to M. tuberculosis)
Anti-TB IgM Antibodies	Negative (No band visible at the IgM test region)	Positive (Visible band indicating acute or recent immunological response)
Anti-TB IgA Antibodies	Negative (No band visible at the IgA test region)	Positive (Visible band indicating active mucosal immune activation)
Control Line (C-Line)	Visible (Colored band present, confirming test validity)	Not Visible (Invalid test; requires immediate retesting with a new device)
Test Line (T-Line)	Not Visible (No colored band, indicating no detectable antibodies)	Visible (Colored band present, indicating detection of anti-TB antibodies)
Sputum AFB Correlation	No acid-fast bacilli observed in sputum smears	Acid-fast bacilli observed, confirming active pulmonary tuberculosis
Molecular Correlation (GeneXpert)	M. tuberculosis DNA not detected	M. tuberculosis DNA detected; rifampicin resistance status reported

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Mycodot by ICT?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists and medical technologists who specialize in infectious disease serology and microbiology.
• Patient-Focused Care: We prioritize patient comfort and safety, ensuring a gentle and professional sample collection experience for patients of all ages.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict internal and external quality control protocols to ensure the highest accuracy of all laboratory results.
• Professional Reporting: Our reports are detailed, clear, and structured to provide clinicians with actionable diagnostic insights.
• Modern Diagnostic Approach: We utilize advanced lateral flow assay devices and state-of-the-art laboratory equipment to process and verify all tests.
• Comfortable Environment: Our diagnostic center is designed to provide a clean, hygienic, and stress-free environment for our patients and their families.
• Convenient Location: Located centrally in Peshawar, our facility is easily accessible to patients from all parts of the city and surrounding districts.
• Commitment to Accurate Diagnosis: We are dedicated to delivering reliable, evidence-based diagnostic services that support effective clinical decision-making and patient care.